The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Unmet needs and treatment perspectives of patients (pts) with previously treated small cell lung cancer (SCLC): A global, qualitative interview study.
 
Samantha Valliant
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Sudhir Unni
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Tara Herrmann
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Sajid Ahmed
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Meredith Venerus
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - IQVIA
Consulting or Advisory Role - IQVIA
 
Friso Coerts
Employment - Daiichi Sankyo Europe GmbH; Pfizer
Stock and Other Ownership Interests - Pfizer
 
Cecilia Jimenez Moreno
Research Funding - Kielo Research (Inst)
 
Dorsa Khazaei
Research Funding - Daiichi Sankyo/UCB Japan (Inst)
 
Tommi Tervonen
Employment - MSD (I)
Consulting or Advisory Role - GlaxoSmithKline; MSD
Research Funding - AstraZeneca; Bayer; CSL Vifor; Daiichi Sankyo; GlaxoSmithKline; Takeda; Teva; UCB
 
Toshiyuki Kozuki
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Jared Weiss
Stock and Other Ownership Interests - Enfuego Therapeutics; Merus; Nuvalent, Inc.; rvmd; Vertex; Vesselon
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; EMD Serono; GlaxoSmithKline; Nanobiotix; PDS Biotechnology; Pharmacosmos
Research Funding - BMS (Inst); Genmab (Inst); Inspirna (Inst); Iovance Biotherapeutics (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); Nurix (Inst); PDS Biotechnology (Inst); Pharmacosmos (Inst); Summit Therapeutics (Inst); TScan Therapeutics (Inst)
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche